Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a
biopharmaceutical company aimed at developing and commercializing
therapies for the treatment of rare genetic diseases of obesity,
today reported financial results and provided a business update for
the second quarter ended June 30, 2021.
“We have made tremendous progress in the second quarter towards
our goal of transforming the care of patients with rare genetic
diseases of obesity globally,” said David Meeker, M.D., Chair,
President and Chief Executive Officer of Rhythm. “We are pleased
with our first full quarter of IMCIVREE® (setmelanotide) commercial
availability in the United States with positive engagements with
patients, prescribers and payors. We recently secured European
Commission marketing authorization for the treatment of obesity and
the control of hunger associated with genetically confirmed
loss-of-function biallelic POMC, including PCSK1, deficiency or
biallelic LEPR deficiency in adults and children 6 years of age and
above, enabling us to expand patient access to IMCIVREE. From a
market access standpoint, we are encouraged that regulatory
authorities, such as National Institute for Health and Care
Excellence (NICE) in the United Kingdom, recognize these obesities
as rare genetic diseases for which there are no available treatment
options.”
Dr. Meeker continued, “In parallel, we are executing on our
clinical development and regulatory strategy to bring setmelanotide
to substantially more patients suffering from rare genetic diseases
of obesity. We look forward to completing supplementary regulatory
submissions in the second half of this year to both the U.S. Food
and Drug Administration (FDA) and European Medicines Agency (EMA),
seeking marketing authorization for setmelanotide for Bardet-Biedl
and Alström syndromes, and we are excited to continue advancing our
broad clinical development program in additional patient
populations. With agreement from both the FDA and EMA, we are
poised to initiate five clinical trials of setmelanotide: the
pivotal Phase 3 EMANATE trial with five sub-studies in heterozygous
POMC, PCSK1 or LEPR deficiency obesities and SRC1 and SH2B1
deficiency obesities, the Phase 2 DAYBREAK trial in 31 additional
genes each with strong or very strong ties to the MC4R pathway, as
well as a Phase 3 pediatrics trial for children younger than 6 and
two registrational trials for our weekly formulation of
setmelanotide. Taken together, we believe these efforts may enable
us to help many more people with rare genetic diseases of obesity
with a potential treatment for their insatiable hunger or
hyperphagia and early-onset, severe obesity.”
Second Quarter and Recent Business
Highlights:
Pipeline and Business Developments:
POMC and LEPR Deficiency Obesities:
- In July 2021, Rhythm announced that the European Commission
(EC) granted marketing authorization to IMCIVREE for the treatment
of obesity and the control of hunger associated with genetically
confirmed loss-of-function biallelic proopiomelanocortin (POMC),
including PCSK1, deficiency or biallelic leptin receptor (LEPR)
deficiency in adults and children 6 years of age and above.
- In Great Britain, Rhythm’s marketing
authorisation application for IMCIVREE is under review by the
Medicines & Healthcare Products Regulatory Agency (MHRA). The
Company today announced that IMCIVREE has been selected for
evaluation as a “Highly Specialised Technology” (HST) by the
National Institute for Health and Care Excellence (NICE). HST is a
specific status reserved for rare and severe diseases.
Bardet-Biedl Syndrome and Alström Syndrome:
- Today, Rhythm provided an update on its regulatory strategy for
setmelanotide for the treatment of Alström syndrome. Based on
feedback from both the FDA and EMA, Rhythm now plans to submit a
supplemental New Drug Application (sNDA) to the FDA and Type II
variation marketing authorization application (MAA) to the EMA in
the second half of 2021, which will cover both BBS and Alström
syndrome.
- Also in July 2021, Rhythm announced a collaborative research
agreement with the Clinical Registry Investigating Bardet-Biedl
Syndrome (CRIBBS) to initiate a population study focused on the
natural history of weight gain, hyperphagia and quality of life in
patients with BBS.
Additional Clinical Development Updates:
Today, Rhythm announced it has reached agreement with the FDA
and EMA on five new Phase 2 and Phase 3 clinical trials, all of
which the Company expects to initiate in the second half of
2021:
- EMANATE: a Phase 3,
randomized, double-blind, placebo-controlled trial to evaluate
setmelanotide in the five genes within the melanocortin-4 receptor
(MC4R) pathway in which Rhythm previously achieved proof of
concept, as announced in January. This trial is comprised of five
independent sub-studies evaluating setmelanotide in patients with:
heterozygous POMC/PCSK1 obesity; heterozygous LEPR obesity; certain
variants of the SRC1; certain variants of SH2B1 genes; or PCSK1
N221D deletions within the MC4R pathway;
- DAYBREAK: an
exploratory, Phase 2, two-stage, placebo-controlled trial of
setmelanotide in patients with variants in one of 31 additional
genes with strong or very strong MC4R pathway relevance. Patients
with a variant in one of the 31 genes who show an initial response
to treatment with setmelanotide will enter stage 2 where they will
be randomized to a placebo withdrawal arm or continuation on
setmelanotide;
- Pediatric patients:
a Phase 3, open-label trial evaluating setmelanotide in children
between the ages of 2 and 6 years old with obesity due to biallelic
POMC, PCSK1 or LEPR deficiency or BBS;
- Weekly formulation:
- Phase 3 study in patients currently
on daily setmelanotide therapy (“switch study”), that is a
randomized, double-blind trial to evaluate the efficacy of daily
and weekly formulations of setmelanotide in patients with obesity
due to biallelic POMC, PCSK1 or LEPR deficiency or BBS;
- Phase 3, randomized, double-blind
study in patients naïve to setmelanotide therapy (“de novo study”),
that includes a cross-over period to evaluate the weekly
formulation of setmelanotide in patients with BBS.
- Hypothalamic
obesity: In July 2021, the Company initiated an
exploratory Phase 2 clinical trial evaluating setmelanotide in
people living with hypothalamic obesity. Hypothalamic obesity is a
rare, acquired form of extreme obesity that occurs following damage
to the hypothalamic regions of the brain, which are responsible for
controlling physiological functions such as hunger and weight
regulation. Rhythm believes a subset of patients with hypothalamic
obesity have the potential to see reductions in weight and hunger
with setmelanotide if their MC4 receptor is sufficiently
intact.
Corporate
- In July 2021, Rhythm announced an exclusive distribution
agreement with Medison Pharma, a leading commercial partner for
highly innovative therapies in international markets, for Medison
to commercialize IMCIVREE in Israel.
- In July 2021, the Company announced the appointments of two new
senior leaders: Pamela Cramer as Chief Human Resources Officer and
Linda Shapiro, M.D., Ph.D., as Senior Vice President,
Clinical.
Key Upcoming Milestones:
Rhythm expects to achieve the following milestones in 2021:
Regulatory Milestones:
- Complete regulatory submissions to both the FDA and the EMA
seeking marketing authorization for setmelanotide for the treatment
of obesity in patients with BBS and Alström syndrome in the second
half of 2021.
Additional Clinical Milestones:
- Present full data from the pivotal Phase 3 trial evaluating
setmelanotide in BBS and Alström syndrome at the 59th Annual
European Society for Paediatric Endocrinology (ESPE) Meeting in
September 2021, following topline data presentations in March and
April;
- Rhythm now anticipates announcing new topline data from the
ongoing exploratory Phase 2 Basket Study evaluating setmelanotide
in patients with obesity due to a variant in the MC4 receptor, as
well as its study in patients with hypothalamic obesity, in the
first quarter of 2022.
Second Quarter 2021 Financial Results:
- Cash Position: As of June 30, 2021, cash, cash
equivalents and short-term investments were approximately $368.2
million, as compared to $172.8 million as of December 31, 2020.
This increase includes net proceeds of $98.4 million received upon
closing the sale of Rhythm’s Rare Pediatric Disease Priority Review
Voucher in February 2021, and net proceeds of approximately $161.7
million from Rhythm’s underwritten public offering of common stock,
which closed in February 2021, partially offset by cash used to
fund operating activities in the first half of 2021.
- Revenue: Product net revenues relating to
sales of IMCIVREE were $0.3 million for the second quarter of 2021.
Rhythm did not generate any product revenues in the second quarter
of 2020 as IMCIVREE was approved for commercial use by the FDA in
November 2020.
- R&D Expenses: R&D expenses were $25.1
million in the second quarter of 2021, as compared to $23.0 million
in the second quarter of 2020. The year-over-year increase was
primarily related to an increase of $2.3 million for purchases of
setmelanotide API and drug product and increase of $1.8 million for
hiring full-time employees to support increased clinical
development activities; these increases were partially offset by a
decrease of $1.9 million due to the absence of development
milestone payments in the current quarter.
- S,G&A Expenses: S,G&A expenses were
$15.5 million for the second quarter of 2021, as compared to $8.9
million for the second quarter of 2020. The year-over-year increase
was primarily related to an increase of $4.2 million in salaries
and benefits associated with additions to Rhythm’s executive
leadership team, increased headcount to support Rhythm’s expanding
business operations as well as establish its commercial operations
in the United States and internationally, an increase of $1.7
million for consulting fees to support U.S. and international
commercial operations and corporate legal and consulting support
for Rhythm’s international expansion, and an increase of $0.5
million for increased office support and insurance costs.
- Net Loss: Net loss was $35.4 million for the
second quarter of 2021, or a net loss per basic and diluted share
of $0.70, as compared to a net loss of $31.1 million for the second
quarter of 2020, or a net loss per basic and diluted share of
$0.71.
Year to Date 2021 Financial Results:
- Revenue: Product revenues relating to sales of
IMCIVREE were $0.3 million for the six months ended June 30, 2021.
Rhythm did not generate any product revenues in the six months
ended June 30, 2020 as IMCIVREE was approved for commercial use by
the FDA in November 2020.
- R&D Expenses: R&D expenses
were $45.0 million for the six months ended June 30,
2021, as compared to $45.5 million for the six months
ended June 30, 2020. The decrease was primarily due to a $2.0
million decrease related to completing the GO-ID genotyping study,
the Phase 3 POMC and LEPR trials and the Phase 2 weekly formulation
in early to mid-2020, as well as a $2.2 million decrease in patent
and regulatory filing costs. These decreases were partially offset
by increased costs related to Rhythm’s ongoing extension study, BBS
and renal studies. In addition, there was an increase of $3.2
million for hiring full-time employees to support increased
clinical development activities and $0.7 million for purchases of
setmelanotide API and drug product.
- S,G&A Expenses: S,G&A expenses
were $30.0 million for the six months ended June 30,
2021, as compared to $21.7 million for the six months
ended June 30, 2020. The increase was primarily due to an
increase of $4.0 million in salaries and benefits associated with
additions to Rhythm’s executive leadership team, increased
headcount to support Rhythm’s expanding business operations as well
as to establish its commercial operations in the United States and
internationally, an increase of $2.1 million for consulting fees to
support U.S. and international commercial operations and corporate
legal and consulting support for Rhythm’s international expansion,
an increase of $0.6 million for increased office support and
insurance, and an increase of $1.6 million associated with the
expenses incurred on the sale of Rhythm’s PRV to Alexion.
- Other income, net: Other income increased by
$99.0 million in the six months ended June 30, 2021 due primarily
to the sale of Rhythm’s PRV in February 2021.
- Provision for income taxes: The Company
recorded a tax provision of $17.0 million for the six months ended
June30, 2021, primarily related to the sale of Rhythm’s PRV, offset
by a tax benefit from ordinary losses. The Company expects to have
sufficient tax losses in the current year to offset the income from
the sale and thus no current year liability is expected.
- Net Income/(Loss): Net income was $8.4
million for the six months ended June 30, 2021, or a net
income per basic and diluted share of $0.17, as compared to a
net loss of $65.3 million for the six months
ended June 30, 2020, or a net loss per basic and diluted share
of $1.48.
Financial Guidance: Based on its current
operating plans, Rhythm expects that its existing cash, cash
equivalents and short-term investments as of June 30, 2021, will be
sufficient to fund its operating expenses and capital expenditure
requirements into at least the second half of 2023.
Conference Call Information
Rhythm Pharmaceuticals will host a live conference call and
webcast at 8:00 a.m. ET today to discuss this update, as
well as review its second quarter 2021 financial results and recent
business activities. The conference call may be accessed by dialing
(844) 498-0570 (domestic) or (409) 983-9726 (international), and
referring to conference ID 6776764. A webcast of the call will be
available under "Events and Presentations" in the Investor
Relations section of the Rhythm Pharmaceuticals website
at http://ir.rhythmtx.com/. The archived webcast will be
available on Rhythm Pharmaceuticals’ website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Rhythm PharmaceuticalsRhythm is a
commercial-stage biopharmaceutical company committed to
transforming the treatment paradigm for people living with rare
genetic diseases of obesity. The Company’s precision medicine,
IMCIVREE (setmelanotide), was approved in November 2020 by the U.S.
Food and Drug Administration (FDA) for chronic weight management in
adult and pediatric patients 6 years of age and older with obesity
due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing
and by the European Commission (EC) in July 2021 for the treatment
of obesity and the control of hunger associated with genetically
confirmed loss-of-function biallelic POMC, including PCSK1,
deficiency or biallelic LEPR deficiency in adults and children 6
years of age and above. IMCIVREE is the first-ever FDA-approved and
EC-authorized therapy for these rare genetic diseases of obesity.
Rhythm is advancing a broad clinical development program for
setmelanotide in other rare genetic diseases of obesity. The
Company is leveraging the Rhythm Engine and the largest known
obesity DNA database - now with approximately 37,500 sequencing
samples - to improve the understanding, diagnosis and care of
people living with severe obesity due to certain genetic
deficiencies. The company is based in Boston, MA.
IMCIVREE®
(setmelanotide) IndicationIn the United States,
IMCIVREE is indicated for chronic weight management in adult and
pediatric patients 6 years of age and older with obesity due to
proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin
type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The condition
must be confirmed by genetic testing demonstrating variants
in POMC, PCSK1, or LEPR genes that are
interpreted as pathogenic, likely pathogenic, or of uncertain
significance (VUS).
In the EU, IMCIVREE is indicated for the treatment of obesity
and the control of hunger associated with genetically confirmed
loss-of-function biallelic POMC, including PCSK1, deficiency or
biallelic LEPR deficiency in adults and children 6 years of age and
above. IMCIVREE should be prescribed and supervised by a physician
with expertise in obesity with underlying genetic etiology.
Limitations of UseIMCIVREE is not indicated for
the treatment of patients with the following conditions as IMCIVREE
would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1, or LEPR deficiency
with POMC, PCSK1, or LEPR variants classified
as benign or likely benign;
- Other types of obesity not related to POMC, PCSK1 or LEPR
deficiency, including obesity associated with other genetic
syndromes and general (polygenic) obesity.
Important Safety Information
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Sexual
adverse reactions may occur in patients treated with IMCIVREE.
Spontaneous penile erections in males and sexual adverse reactions
in females occurred in clinical studies with IMCIVREE. Instruct
patients who have an erection lasting longer than 4 hours to seek
emergency medical attention.
Depression and Suicidal Ideation: Some
drugs that target the central nervous system, such as IMCIVREE, may
cause depression or suicidal ideation. Monitor patients for new
onset or worsening of depression. Consider discontinuing IMCIVREE
if patients experience suicidal thoughts or behaviors.
Skin Pigmentation and Darkening of Pre-Existing
Nevi: IMCIVREE may cause generalized increased skin
pigmentation and darkening of pre-existing nevi due to its
pharmacologic effect. This effect is reversible upon
discontinuation of the drug. Perform a full body skin examination
prior to initiation and periodically during treatment with IMCIVREE
to monitor pre-existing and new skin pigmentary
lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol
Preservative in Neonates and Low Birth Weight
Infants: IMCIVREE is not approved for use in neonates
or infants.
ADVERSE REACTIONS
- The most common adverse reactions (incidence ≥23%) were
injection site reactions, skin hyperpigmentation, nausea, headache,
diarrhea, abdominal pain, back pain, fatigue, vomiting, depression,
upper respiratory tract infection, and spontaneous penile
erection.
USE IN SPECIFIC POPULATIONSDiscontinue IMCIVREE
when pregnancy is recognized unless the benefits of therapy
outweigh the potential risks to the fetus.
Treatment with IMCIVREE is not recommended for use while
breastfeeding.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm
Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
See Full Prescribing Information for IMCIVREE.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the potential, safety, efficacy, and regulatory and
clinical progress of setmelanotide, including the anticipated
timing for initiation of clinical trials and release of clinical
trial data and our expectations surrounding potential regulatory
submissions, approvals and timing thereof, our business strategy
and plans, including regarding commercialization of setmelanotide,
our participation in upcoming events and presentations, and the
sufficiency of our cash, cash equivalents and short-term
investments to fund our operations. Statements using word such as
“expect”, “anticipate”, “believe”, “may”, “will” and similar terms
are also forward-looking statements. Such statements are subject to
numerous risks and uncertainties, including, but not limited to,
the impact of our management transition, our ability to enroll
patients in clinical trials, the design and outcome of clinical
trials, the impact of competition, the ability to achieve or obtain
necessary regulatory approvals, risks associated with data analysis
and reporting, our liquidity and expenses, the impact of the
COVID-19 pandemic on our business and operations, including our
preclinical studies, clinical trials and commercialization
prospects, and general economic conditions, and the other important
factors discussed under the caption “Risk Factors” in our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2021 and our
other filings with the Securities and Exchange Commission. Except
as required by law, we undertake no obligations to make any
revisions to the forward-looking statements contained in this
release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of
new information, future developments or otherwise.
Condensed Consolidated Statements of Operations
and Comprehensive Income (Loss)(in thousands, except share and per
share data)(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Product revenue, net |
|
$ |
274 |
|
|
$ |
— |
|
|
$ |
309 |
|
|
$ |
— |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
137 |
|
|
|
— |
|
|
|
141 |
|
|
|
— |
|
Research and development |
|
|
25,104 |
|
|
|
22,997 |
|
|
|
45,015 |
|
|
|
45,501 |
|
Selling, general, and administrative |
|
|
15,465 |
|
|
|
8,921 |
|
|
|
29,983 |
|
|
|
21,717 |
|
Total costs and expenses |
|
|
40,706 |
|
|
|
31,918 |
|
|
|
75,139 |
|
|
|
67,218 |
|
Loss from operations |
|
|
(40,432 |
) |
|
|
(31,918 |
) |
|
|
(74,830 |
) |
|
|
(67,218 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Other income |
|
|
— |
|
|
|
— |
|
|
|
100,000 |
|
|
|
— |
|
Interest income, net |
|
|
21 |
|
|
|
801 |
|
|
|
175 |
|
|
|
1,937 |
|
Total other income, net |
|
|
21 |
|
|
|
801 |
|
|
|
100,175 |
|
|
|
1,937 |
|
Income (loss) before
taxes |
|
|
(40,411 |
) |
|
|
(31,117 |
) |
|
|
25,345 |
|
|
|
(65,281 |
) |
Provision for income
taxes |
|
|
(5,022 |
) |
|
|
— |
|
|
|
16,984 |
|
|
|
— |
|
Net income (loss) |
|
$ |
(35,389 |
) |
|
$ |
(31,117 |
) |
|
$ |
8,361 |
|
|
$ |
(65,281 |
) |
Net income (loss) per
share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.70 |
) |
|
$ |
(0.71 |
) |
|
$ |
0.17 |
|
|
$ |
(1.48 |
) |
Diluted |
|
$ |
(0.70 |
) |
|
$ |
(0.71 |
) |
|
$ |
0.17 |
|
|
$ |
(1.48 |
) |
Weighted-average common shares
outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
50,209,484 |
|
|
|
44,098,860 |
|
|
|
48,931,127 |
|
|
|
44,074,352 |
|
Diluted |
|
|
50,209,484 |
|
|
|
44,098,860 |
|
|
|
49,644,704 |
|
|
|
44,074,352 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income
(loss): |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
(35,389 |
) |
|
$ |
(31,117 |
) |
|
$ |
8,361 |
|
|
$ |
(65,281 |
) |
Unrealized (loss) gain on marketable securities |
|
|
79 |
|
|
|
567 |
|
|
|
(28 |
) |
|
|
630 |
|
Comprehensive income
(loss) |
|
$ |
(35,310 |
) |
|
$ |
(30,550 |
) |
|
$ |
8,333 |
|
|
$ |
(64,651 |
) |
Rhythm Pharmaceuticals, Inc.Condensed
Consolidated Balance Sheets(in thousands, except share and per
share data)(Unaudited)
|
|
June 30, |
|
December 31, |
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
69,339 |
|
|
$ |
100,854 |
|
Short-term investments |
|
|
298,815 |
|
|
|
71,938 |
|
Prepaid expenses and other current assets |
|
|
10,300 |
|
|
|
8,876 |
|
Total current assets |
|
|
378,454 |
|
|
|
181,668 |
|
Property and
equipment, net |
|
|
3,051 |
|
|
|
3,195 |
|
Right-of-use
asset |
|
|
1,671 |
|
|
|
1,807 |
|
Intangible assets,
net |
|
|
4,886 |
|
|
|
— |
|
Restricted
cash |
|
|
328 |
|
|
|
403 |
|
Total assets |
|
$ |
388,390 |
|
|
$ |
187,073 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
5,009 |
|
|
$ |
4,900 |
|
Accrued expenses and other current liabilities |
|
|
11,880 |
|
|
|
12,559 |
|
Lease liability |
|
|
570 |
|
|
|
535 |
|
Total current liabilities |
|
|
17,459 |
|
|
|
17,994 |
|
Long-term
liabilities: |
|
|
|
|
|
|
Deferred tax
liability |
|
|
16,984 |
|
|
|
— |
|
Lease
liability |
|
|
2,258 |
|
|
|
2,551 |
|
Total liabilities |
|
|
36,701 |
|
|
|
20,545 |
|
Commitments and
contingencies (Note 5) |
|
|
|
|
|
|
Stockholders’
equity: |
|
|
|
|
|
|
Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no
shares issued and outstanding at June 30, 2021 and
December 31, 2020 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value: 120,000,000 shares authorized;
50,226,739 and 44,235,903 shares issued and outstanding
June 30, 2021 and December 31, 2020,
respectively |
|
|
50 |
|
|
|
44 |
|
Additional paid-in capital |
|
|
802,584 |
|
|
|
625,762 |
|
Accumulated other comprehensive income |
|
|
21 |
|
|
|
49 |
|
Accumulated deficit |
|
|
(450,966 |
) |
|
|
(459,327 |
) |
Total stockholders’ equity |
|
|
351,689 |
|
|
|
166,528 |
|
Total liabilities and stockholders’ equity |
|
$ |
388,390 |
|
|
$ |
187,073 |
|
Corporate Contact:David ConnollyHead of
Investor Relations and Corporate CommunicationsRhythm
Pharmaceuticals, Inc.857-264-4280dconnolly@rhythmtx.com
Investor Contact:Hannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact:Adam DaleyBerry & Company
Public Relations212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Apr 2023 to Apr 2024